Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin a dipeptidyl peptidase-4 inhibitor in healthy subjects

摘要

AIMTo investigate the effect of co-administration of rifampicin, a potent inducer of cytochrome P450 (CYP) 3A4 enzymes, on the pharmacokinetics (PK) and pharmacodynamics (PD) of saxagliptin and 5-hydroxy saxagliptin in healthy subjects. Saxagliptin is metabolized by CYP3A4/3A5 to 5-hydroxy saxagliptin, its major pharmacologically active metabolite.